Ideal cystoscopic interval after nephroureterectomy in patients with upper tract urothelial carcinoma.

IF 2.8 2区 医学 Q2 UROLOGY & NEPHROLOGY World Journal of Urology Pub Date : 2024-11-06 DOI:10.1007/s00345-024-05302-9
Shuto Konta, Kohei Hashimoto, Tetsuya Shindo, Ko Kobayashi, Toshiaki Tanaka, Naoya Masumori
{"title":"Ideal cystoscopic interval after nephroureterectomy in patients with upper tract urothelial carcinoma.","authors":"Shuto Konta, Kohei Hashimoto, Tetsuya Shindo, Ko Kobayashi, Toshiaki Tanaka, Naoya Masumori","doi":"10.1007/s00345-024-05302-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to clarify the appropriate cystoscopic interval after nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC) using a hypothetical model.</p><p><strong>Methods: </strong>A total of 155 patients who underwent NU in 15 years were retrospectively evaluated. Three hypothetical models for surveillance intervals were created: 3 (model 1), 6 (model 2) and 12 months (model 3). We superimposed these models on the actual surveillance of each patient and analyzed the observed timing of recurrence. The time from recurrence to scheduled cystoscopy (timeRCS) was defined as the time from recurrence to estimated cystoscopy. The gap risk ratio was calculated based on the average of timeRCS for model 1 at 0-1 year after surgery.</p><p><strong>Results: </strong>The median follow-up was 20.5 months. Intravesical recurrence was observed in 63 patients (40.6%). The 3-year intravesical recurrence-free survival rate in patients without a history of bladder cancer before NU was significantly higher than in those with a history of bladder cancer (61% vs. 42%, P = 0.034). The medians of timeRCS for models 1, 2, and 3 were 1.9, 2.9, and 8.4 months, respectively. The gap risk ratios for model 1 at 1-3 years, model 2 at 2-3 years for patients with a history of bladder cancer, and model 2 at 1-3 years for patients without a history of bladder cancer were less than 1.0.</p><p><strong>Conclusion: </strong>Model analysis shows that the cystoscopic follow-up interval can be extended depending on the presence or absence of a history of bladder cancer and the time after NU.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"42 1","pages":"629"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00345-024-05302-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The purpose of this study was to clarify the appropriate cystoscopic interval after nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC) using a hypothetical model.

Methods: A total of 155 patients who underwent NU in 15 years were retrospectively evaluated. Three hypothetical models for surveillance intervals were created: 3 (model 1), 6 (model 2) and 12 months (model 3). We superimposed these models on the actual surveillance of each patient and analyzed the observed timing of recurrence. The time from recurrence to scheduled cystoscopy (timeRCS) was defined as the time from recurrence to estimated cystoscopy. The gap risk ratio was calculated based on the average of timeRCS for model 1 at 0-1 year after surgery.

Results: The median follow-up was 20.5 months. Intravesical recurrence was observed in 63 patients (40.6%). The 3-year intravesical recurrence-free survival rate in patients without a history of bladder cancer before NU was significantly higher than in those with a history of bladder cancer (61% vs. 42%, P = 0.034). The medians of timeRCS for models 1, 2, and 3 were 1.9, 2.9, and 8.4 months, respectively. The gap risk ratios for model 1 at 1-3 years, model 2 at 2-3 years for patients with a history of bladder cancer, and model 2 at 1-3 years for patients without a history of bladder cancer were less than 1.0.

Conclusion: Model analysis shows that the cystoscopic follow-up interval can be extended depending on the presence or absence of a history of bladder cancer and the time after NU.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
上尿路上皮癌患者肾切除术后理想的膀胱镜检查间隔时间。
目的:本研究的目的是通过一个假设模型,明确上尿路上皮癌(UTUC)肾切除术(NU)后膀胱镜检查的适当间隔时间:方法: 对 15 年来接受肾切除术的 155 名患者进行了回顾性评估。建立了三种监测间隔假设模型:3个月(模型1)、6个月(模型2)和12个月(模型3)。我们将这些模型叠加到每位患者的实际监测中,并分析了观察到的复发时间。从复发到预定膀胱镜检查的时间(timeRCS)被定义为从复发到估计膀胱镜检查的时间。根据模型1中术后0-1年的平均时间RCS计算间隙风险比:中位随访时间为 20.5 个月。63例患者(40.6%)观察到膀胱内复发。NU 前无膀胱癌病史患者的 3 年无膀胱内复发生存率明显高于有膀胱癌病史的患者(61% 对 42%,P = 0.034)。模型1、2和3的时间RCS中值分别为1.9、2.9和8.4个月。对于有膀胱癌病史的患者,模型 1 在 1-3 年时、模型 2 在 2-3 年时、模型 2 在 1-3 年时对于无膀胱癌病史的患者的差距风险比均小于 1.0:模型分析表明,膀胱镜随访时间间隔可根据有无膀胱癌病史以及NU后的时间而延长。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Urology
World Journal of Urology 医学-泌尿学与肾脏学
CiteScore
6.80
自引率
8.80%
发文量
317
审稿时长
4-8 weeks
期刊介绍: The WORLD JOURNAL OF UROLOGY conveys regularly the essential results of urological research and their practical and clinical relevance to a broad audience of urologists in research and clinical practice. In order to guarantee a balanced program, articles are published to reflect the developments in all fields of urology on an internationally advanced level. Each issue treats a main topic in review articles of invited international experts. Free papers are unrelated articles to the main topic.
期刊最新文献
Can suction technology be a potential game changer that reshapes pediatric endourological interventions? Results from a scoping review. Does race and insurance status play a role in high-grade renal trauma in the pediatric population? - An analysis from the traumatic renal injury collaborative in kids (TRICK) consortium. Risk factors for kidney cancer and socio-occupational category: significant impact of chlorinated solvents (UroCCR 111). RAM2: animal study for safety evaluation of the new artificial urinary sphincter uroactive on a castrated RAM model. Correction: Role of neoadjuvant chemotherapy in patients with locally advanced and clinically positive nodes Upper Tract Urothelial Carcinoma treated with Nephroureterectomy: real-world data from the ROBUUST 2.0 Registry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1